EP Patent

EP2968258B1 — Dual sglt1/sglt2 inhibitors

Assigned to Janssen Pharmaceutica NV · Expires 2020-02-12 · 6y expired

What this patent protects

Patent listed against Invokana.

Drugs covered by this patent

Patent Metadata

Patent number
EP2968258B1
Jurisdiction
EP
Classification
—
Expires
2020-02-12
Drug substance claim
No
Drug product claim
No
Assignee
Janssen Pharmaceutica NV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.